Logo

Chugai's Nemolizumab Receives the US FDA's Breakthrough Therapy Designation to Treat Pruritus Associated with Prurigo Nodularis

Share this

Chugai's Nemolizumab Receives the US FDA's Breakthrough Therapy Designation to Treat Pruritus Associated with Prurigo Nodularis

Shots:

  • Nemolizumab is a novel therapy targeting IL-31 receptor A developed utilizing Chugai’s antibody engineering technology ACT-Ig. The 8th BT designation is granted to the Chugai based on P-II clinical study conducted by Galderma and the results were presented at EADV 2019
  • The BT designation is granted to serious or life-threatening disease therapies demonstrate a substantial improvement over existing therapies on one or more significant preliminary research endpoints
  • Galderma is initiating the P-III trial for nemolizumab in adults with prurigo nodularis in 2020. In 2016- Chugai and Galderma signed a global license agreement for nemolizumab (CIM331)- a novel biologic for skin diseases

Click here ­to­ read full press release/ article | Ref: Chugai  | Image: Chugai


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions